WO2020249120A1 - 氨基硫醇类化合物作为脑神经或心脏保护剂的用途 - Google Patents
氨基硫醇类化合物作为脑神经或心脏保护剂的用途 Download PDFInfo
- Publication number
- WO2020249120A1 WO2020249120A1 PCT/CN2020/095998 CN2020095998W WO2020249120A1 WO 2020249120 A1 WO2020249120 A1 WO 2020249120A1 CN 2020095998 W CN2020095998 W CN 2020095998W WO 2020249120 A1 WO2020249120 A1 WO 2020249120A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- methylamino
- mercapto
- propionamide
- amino
- Prior art date
Links
- 0 CNC(C1)(C1S*)C(N[C@@](CS*)C(NC)=O)=O Chemical compound CNC(C1)(C1S*)C(N[C@@](CS*)C(NC)=O)=O 0.000 description 4
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
A组 | 空白对照组 |
B组 | 缺血再灌注造模组 |
C组 | 再灌注前5min给药化合物B(100mg/kg ip) |
D组 | 再灌注前2.5h给药化合物A(400mg/kg po) |
E组 | 再灌注前2.5h给药化合物A(800mg/kg po) |
F组 | 再灌注前给药依拉达丰(XH-001)(3mg/kg,iv) |
G组 | 再灌注前5min给药氨磷汀(XH-002)(100mg/kg,ip) |
Claims (13)
- 式(I)化合物或选自下述组(II)任一的化合物在制备用作脑神经保护剂或心脏保护剂的药物中的用途,其中所述式(I)化合物为其中,A 1选自-C(O)NR 8-、-S(O) 2-NR 8-、-S(O)NR 8-和-R 7-NR 8-;A 2选自羰基、磺酰基、亚硫酰基、取代或未取代的C 1-6烷基;R 1和R 5可相同或不同,选自氢、取代或未取代的C 1-C 5烷基或杂烷基;R 2和R 6可相同或不同,选自取代或未取代的C 1-C 5烷基或杂烷基;n为0-20000的整数;R 3、R 4独立地选自氢、X、取代或未取代的C 1-6烷基;X选自F、Cl、Br和I;R 7选自取代或未取代的C 1-C 6烷基,R 8选自氢、取代或未取代的C 1-C 6烷基;或其立体异构体或其药学上可接受的盐、前药和溶剂化物;组(II)化合物:(R)-2-(((R)-3-巯基-2-(甲基氨基)丙基)氨基)-3-(甲基氨基)丙烷-1-硫醇或其盐酸盐(化合物1)、(R)-N-((R)-3-((2-甲氧基丙-2-基)硫基)-1-(甲基氨基)-1-氧代丙烷-2-基)-2,2,3-三甲基噻唑烷-4-甲酰胺(化合物2)和(R)-2,2,3-三甲基-N-((6R,9R)-3,3,12,12-四甲基-6-(甲基氨基甲酰基)-8-氧代-2,13-二氧杂-4,11-二硫杂-7-氮杂四癸烷-9-基)噻唑烷-4-甲酰胺(化合物3)、(R)-3-巯基-N-((R)-3-巯基-1-((2-(甲基氨基)乙基)氨基)-1-氧代丙烷-2-基)-2-((2-(甲基氨基)乙基)氨基)丙酰胺、(R)-N-((7R,10R)-6,9-二氧代-13,13,13-三苯基-7-(三苯甲基硫基甲基)-12-硫杂-2,5,8-三氮杂十三烷-10-基)-3-巯基-2-(2-(甲基氨基)乙基氨基)丙酰胺、(R)-N-((R)-3,3-二甲基-7-氧代-2-氧杂-4-硫杂-8,11-二氮杂十二烷-6-基)-3-(2-甲氧基丙-2-基硫基)-2-(2,2,3-三甲基咪唑烷-1-基)丙酰胺和(R)-N-((R)-3,3-二甲基-7-氧代-2-氧杂-4-硫杂-8,11-二氮杂十二烷-6-基)-3-(2-甲氧基丙-2-基硫基)-2-((R)-3-(2-甲氧基丙-2-基硫基)-2-(2,2,3-三甲基咪唑烷- 1-基)丙酰氨基)丙酰胺。
- 权利要求1的用途,其中所述式(I)化合物为(R)-3-巯基-N-((R)-3-巯基-1-(甲基氨基)-1-氧代丙-2-基)-2-(甲基氨基)丙酰胺;或(R)-3-巯基-N-((R)-3-巯基-1-(((R)-3-巯基-1-(甲基氨基)-1-氧代丙-2-基)氨基)-1-氧代丙-2-基)-2-(甲基氨基)丙酰胺。
- 权利要求1的用途,其中所述式(I)化合物为(R)-3-巯基-N-((R)-3-巯基-1-(甲基氨基)-1-氧代丙-2-基)-2-(甲基氨基)丙酰胺或其药学上可接受的盐;或(R)-3-巯基-N-((R)-3-巯基-1-(((R)-3-巯基-1-(甲基氨基)-1-氧代丙-2-基)氨基)-1-氧代丙-2-基)-2-(甲基氨基)丙酰胺或其药学上可接受的盐。
- 权利要求1的用途,其中所述式(I)化合物为(R)-3-巯基-N-((R)-3-巯基-1-(甲基氨基)-1-氧代丙-2-基)-2-(甲基氨基)丙酰胺三氟乙酸盐;或(R)-3-巯基-N-((R)-3-巯基-1-(((R)-3-巯基-1-(甲基氨基)-1-氧代丙-2-基)氨基)-1-氧代丙-2-基)-2-(甲基氨基)丙酰胺三氟乙酸盐。
- 权利要求1的用途,其中所述式(I)化合物为(R)-3-巯基-N-((R)-3-巯基-1-(甲基氨基)-1-氧代丙-2-基)-2-(甲基氨基)丙酰胺盐酸盐;或(R)-3-巯基-N-((R)-3-巯基-1-(((R)-3-巯基-1-(甲基氨基)-1-氧代丙-2-基)氨基)-1-氧代丙-2-基)-2-(甲基氨基)丙酰胺盐酸盐。
- 权利要求1-5任一项的用途,其中所述化合物作为脑神经保护剂,用于预防或治疗下述疾病或病症中的一种或多种:脑卒中,包括缺血性和出血性脑卒中;在缺血性脑卒中治疗过程中诱发的二次损伤,即脑缺血再灌注损伤;动脉粥样硬化、脑溢血、高血压、心肌梗塞、心绞痛、冠心病、心肌纤维化、心脏病、心律不齐、头晕、失眠等;静脉曲张、水肿等与血管通透性升高有关的疾病;老年性疾病,例如帕金森症、脑萎缩、老年性痴呆;其它脑神经损伤类疾病,包括但不限于脑外伤、脑血管硬化(脑溢血、脑血栓)后遗症、脑炎与脑膜炎后遗症、脱髓鞘疾病、局部缺血、缺氧、脑血管意外、代谢失调、毒性作用、神经毒性作用、外科手术、医原性影响、压力、质量效应、出血、热、化学因素、辐射、血管痉挛、神经变性性疾病、神经变性性病变、感染、癫痫等原因造成的神经损伤;休克治疗、动脉搭桥术、溶栓疗法、经皮腔内冠脉血管成形术、心脏外科体外循环、心肺脑复苏、或断肢再植和器官移植;系统性硬皮病或肌肉侧索硬化症。
- 权利要求6的用途,其中所述化合物作为脑神经保护剂,用于预防 或治疗脑卒中。
- 权利要求6的用途,其中所述化合物作为脑神经保护剂,用于预防或治疗缺血性脑卒中。
- 权利要求6的用途,其中所述化合物作为脑神经保护剂,用于急性缺血性脑卒中。
- 权利要求1的用途,其中所述化合物作为心脏保护剂,用于预防或治疗心肌缺血或由心肌缺血引起的心肌梗塞或心脑缺血再灌注损伤。
- 权利要求1-10中任一项的用途,其中所述化合物的剂量为约9-16200mg/kg/天。
- 化合物或其药用盐,选自(R)-2-(((R)-3-巯基-2-(甲基氨基)丙基)氨基)-3-(甲基氨基)丙烷-1-硫醇、(R)-N-((R)-3-((2-甲氧基丙-2-基)硫基)-1-(甲基氨基)-1-氧代丙烷-2-基)-2,2,3-三甲基噻唑烷-4-甲酰胺、(R)-2,2,3-三甲基-N-((6R,9R)-3,3,12,12-四甲基-6-(甲基氨基甲酰基)-8-氧代-2,13-二氧杂-4,11-二硫杂-7-氮杂四癸烷-9-基)噻唑烷-4-甲酰胺、(R)-3-巯基-N-((R)-3-巯基-1-((2-(甲基氨基)乙基)氨基)-1-氧代丙烷-2-基)-2-((2-(甲基氨基)乙基)氨基)丙酰胺、(R)-N-((7R,10R)-6,9-二氧代-13,13,13-三苯基-7-(三苯甲基硫基甲基)-12-硫杂-2,5,8-三氮杂十三烷-10-基)-3-巯基-2-(2-(甲基氨基)乙基氨基)丙酰胺、(R)-N-((R)-3,3-二甲基-7-氧代-2-氧杂-4-硫杂-8,11-二氮杂十二烷-6-基)-3-(2-甲氧基丙-2-基硫基)-2-(2,2,3-三甲基咪唑烷-1-基)丙酰胺和(R)-N-((R)-3,3-二甲基-7-氧代-2-氧杂-4-硫杂-8,11-二氮杂十二烷-6-基)-3-(2-甲氧基丙-2-基硫基)-2-((R)-3-(2-甲氧基丙-2-基硫基)-2-(2,2,3-三甲基咪唑烷-1-基)丙酰氨基)丙酰胺。
- 权利要求1-5中的化合物或权利要求12的化合物在制备用于治疗和/或预防辐射损伤的药物、化疗药损伤的药物、化妆品、抗肿瘤药物中的用途。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20821703.4A EP3984993A4 (en) | 2019-06-13 | 2020-06-13 | USE OF AMINOTHIOL COMPOUNDS AS CRANIAL NERVE OR CARDIAC PROTECTIVE AGENT |
AU2020293522A AU2020293522B2 (en) | 2019-06-13 | 2020-06-13 | Use of aminothiol compounds as cerebral nerve or heart protective agent |
JP2021573818A JP2022537518A (ja) | 2019-06-13 | 2020-06-13 | 脳神経または心臓保護剤としてのアミノチオール系化合物の使用 |
US17/618,870 US20220259164A1 (en) | 2019-06-13 | 2020-06-13 | Use of aminothiol compounds as cerebral nerve or heart protective agent |
CA3142963A CA3142963A1 (en) | 2019-06-13 | 2020-06-13 | Use of aminothiol compounds as cerebral nerve or heart protective agent |
CN202080043052.0A CN114072381B (zh) | 2019-06-13 | 2020-06-13 | 氨基硫醇类化合物作为脑神经或心脏保护剂的用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019091065 | 2019-06-13 | ||
CNPCT/CN2019/091065 | 2019-06-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020249120A1 true WO2020249120A1 (zh) | 2020-12-17 |
WO2020249120A9 WO2020249120A9 (zh) | 2021-12-16 |
Family
ID=73781951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/095998 WO2020249120A1 (zh) | 2019-06-13 | 2020-06-13 | 氨基硫醇类化合物作为脑神经或心脏保护剂的用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220259164A1 (zh) |
EP (1) | EP3984993A4 (zh) |
JP (1) | JP2022537518A (zh) |
CN (1) | CN114072381B (zh) |
AU (1) | AU2020293522B2 (zh) |
CA (1) | CA3142963A1 (zh) |
WO (1) | WO2020249120A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113768940A (zh) * | 2021-08-25 | 2021-12-10 | 中国辐射防护研究院 | 一种放射性肺损伤的防护方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1283994A (zh) * | 1997-12-09 | 2001-02-14 | 美国生物科学有限公司 | 使用氨基硫醇化合物治疗神经和肾疾病和治疗毒性的方法 |
CN1679488A (zh) * | 2004-04-06 | 2005-10-12 | 欧莱雅 | 二巯基酰胺在永久性再成型角蛋白纤维中的应用 |
CN103772245A (zh) * | 2012-10-26 | 2014-05-07 | 中国医学科学院放射医学研究所 | 取代的l-半胱氨酸类化合物及其制法和用途 |
CN106432014A (zh) | 2016-09-05 | 2017-02-22 | 中国医学科学院放射医学研究所 | 胺基硫醇类化合物及其制备方法和其在辐射防护中的应用 |
WO2017140754A1 (fr) * | 2016-02-17 | 2017-08-24 | Advanced Biodesign | Procédé de préparation de composés aminothiolester et leurs sels |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010014953A1 (en) * | 2008-08-01 | 2010-02-04 | The Regents Of The University Of Colorado, A Body Corporate | Prolonged administration of a dithiol anti-oxidant protects against ventricular remodeling |
-
2020
- 2020-06-13 JP JP2021573818A patent/JP2022537518A/ja active Pending
- 2020-06-13 AU AU2020293522A patent/AU2020293522B2/en active Active
- 2020-06-13 WO PCT/CN2020/095998 patent/WO2020249120A1/zh active Application Filing
- 2020-06-13 US US17/618,870 patent/US20220259164A1/en active Pending
- 2020-06-13 EP EP20821703.4A patent/EP3984993A4/en active Pending
- 2020-06-13 CN CN202080043052.0A patent/CN114072381B/zh active Active
- 2020-06-13 CA CA3142963A patent/CA3142963A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1283994A (zh) * | 1997-12-09 | 2001-02-14 | 美国生物科学有限公司 | 使用氨基硫醇化合物治疗神经和肾疾病和治疗毒性的方法 |
CN1679488A (zh) * | 2004-04-06 | 2005-10-12 | 欧莱雅 | 二巯基酰胺在永久性再成型角蛋白纤维中的应用 |
CN103772245A (zh) * | 2012-10-26 | 2014-05-07 | 中国医学科学院放射医学研究所 | 取代的l-半胱氨酸类化合物及其制法和用途 |
WO2017140754A1 (fr) * | 2016-02-17 | 2017-08-24 | Advanced Biodesign | Procédé de préparation de composés aminothiolester et leurs sels |
CN106432014A (zh) | 2016-09-05 | 2017-02-22 | 中国医学科学院放射医学研究所 | 胺基硫醇类化合物及其制备方法和其在辐射防护中的应用 |
WO2018041245A1 (zh) | 2016-09-05 | 2018-03-08 | 中国医学科学院放射医学研究所 | 胺基硫醇类化合物及其制备方法和其在辐射防护中的应用 |
Non-Patent Citations (2)
Title |
---|
DRAGOJEVIC-SIMIC VIKTORIJA M; DOBRIC SILVA L J; BOKONJIC DUBRAVKO R; VUCINIC ZARKO M; SINOVEC SNEZANA M; JACEVIC VESNA M; DOGOVIC : "Amifostine protection against doxorubicin cardiotoxicity in rats", ANTI-CANCER DRUGS, vol. 15, no. 2, 1 February 2004 (2004-02-01), pages 169 - 178, XP009524912, ISSN: 0959-4973, DOI: 10.1097/01.cad.0000114633.38337.5f * |
See also references of EP3984993A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113768940A (zh) * | 2021-08-25 | 2021-12-10 | 中国辐射防护研究院 | 一种放射性肺损伤的防护方法 |
Also Published As
Publication number | Publication date |
---|---|
CN114072381A (zh) | 2022-02-18 |
CN114072381B (zh) | 2024-02-27 |
EP3984993A1 (en) | 2022-04-20 |
AU2020293522B2 (en) | 2024-01-25 |
AU2020293522A1 (en) | 2022-01-20 |
EP3984993A4 (en) | 2023-07-19 |
US20220259164A1 (en) | 2022-08-18 |
CA3142963A1 (en) | 2020-12-17 |
WO2020249120A9 (zh) | 2021-12-16 |
JP2022537518A (ja) | 2022-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5841672B2 (ja) | N−ベンジルアニリン誘導体及びその使用 | |
BR112016009488B1 (pt) | piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica | |
TWI710555B (zh) | 新穎水溶性前藥 | |
WO2020020231A1 (zh) | 一类双季铵化合物及其制备方法和用途 | |
BR112014011641B1 (pt) | composto, e , composição | |
BR112020025701A2 (pt) | Processo de produção e intermediários para um composto de pirrolo[2,3-d]pirimidina e seu uso | |
WO2020249120A1 (zh) | 氨基硫醇类化合物作为脑神经或心脏保护剂的用途 | |
BR112017005713B1 (pt) | Composto de fórmula (i) e composição farmacêutica | |
WO2020177291A1 (zh) | 法舒地尔复合盐及其制备方法和用途 | |
WO2023216533A1 (zh) | 一种吲哚生物碱及其制备方法与应用 | |
ES2691530T3 (es) | 2,3,5-trihidroxi-androst-6-ona y métodos de preparación y uso de la misma | |
JP2014528460A (ja) | ブチルフタリドの誘導体、並びにその製造法及び使用 | |
WO2015085968A1 (zh) | 用于心脑血管疾病的喹唑啉衍生物 | |
JP2012006918A (ja) | イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤 | |
EP4174068A1 (en) | Novel compound, and pharmaceutical composition for preventing or treating resistant cancer, comprising same | |
WO2021063373A1 (zh) | 一种trpv1激动剂及其制备方法和用途 | |
BR112019013493A2 (pt) | Compostos heterocíclicos e seus usos | |
CN113387909B (zh) | 2,3-环氧丁二酰衍生物的医药用途 | |
WO2021150697A1 (en) | N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents | |
WO2020038279A1 (zh) | 取代吡唑类化合物、其制备方法、药物组合物及用途 | |
CN112218878A (zh) | Ntcp抑制剂 | |
WO2023246924A1 (zh) | 苯并噻唑化合物及其应用 | |
CN116874485B (zh) | 一种具有降血压作用的螺环化合物的制备及其用途 | |
WO2023246925A1 (zh) | 酯类化合物及其应用 | |
WO2021196884A1 (zh) | 邻苯二酚及衍生物在制备用于治疗睡眠障碍药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20821703 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3142963 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021573818 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2020821703 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2020821703 Country of ref document: EP Effective date: 20220113 |
|
ENP | Entry into the national phase |
Ref document number: 2020293522 Country of ref document: AU Date of ref document: 20200613 Kind code of ref document: A |